ArticlePloS one2026
Prevalence and correlates of low-level viremia and viral load non-suppression among adults on HIV treatment: Results from the Tanzania HIV Impact Survey, 2022-2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile HIV viral load (VL) testing remained a critical approach for monitoring antiretroviral therapy (ART) effectiveness among people living with HIV (PLHIV), limited national data existed on the magnitude and factors associated with key VL thresholds, including low-level viremia (LLV) and VL non-suppression in Tanzania. We analyzed the prevalence and socio-demographic and behavioral factors associated with LLV and VL non-suppression among PLHIV on ART participating in a nationally representative survey.
methodsWe analyzed data from the Tanzania HIV Impact Survey (THIS) 2022-2023 among PLHIV aged 15 years and older. The analysis included 1,485 PLHIV on ART with VL results. Laboratory-based testing was conducted for qualitative detection of antiretroviral (ARV) drugs and quantitative evaluation of VL. Three VL levels were computed for the analyses: undetectable VL (<50 copies/mL); LLV (50-999 copies/mL); and VL non-suppression (≥1000 copies/mL). Unweighted absolute numbers and weighted percentages were reported for descriptive analysis. We used modified Poisson regression models to examine separately the prevalence and factors associated with LLV and VL non-suppression. We reported adjusted prevalence ratios (aPR), 95% confidence intervals (CIs) and p-values <0.05 were considered statistically significant.
resultsOverall, 76% of PLHIV in Tanzania had undetectable VL, 18% had LLV, and 6% had VL non-suppression. Among PLHIV with either LLV or undetectable VL, 19.5% had LLV and after multivariable adjustment, absence of ARV drugs detected in blood was the only factor significantly associated with LLV. Additionally, among PLHIV with either VL non-suppression or undetectable VL, 7.2% had VL non-suppression and after multivariable adjustment, absence of ARV drugs detected in blood and alcohol use were associated with VL non-suppression.
conclusionIn this nationally representative analysis of PLHIV in Tanzania, most people had undetectable viral load, while LLV was common and VL non-suppression was less frequent. Absence of ARV drugs detected in blood was associated with both LLV and VL non-suppression, underscoring the importance of recent ART exposure. These findings suggested that LLV warranted programmatic attention alongside VL non-suppression to support sustained viral suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.